Novavax
NVAX
$4.09
Share price
3.54%
Change (1 day)
-46.68%
Change (1 year)
Categories
Novavax (NVAX) - P/B ratio
P/B ratio as of April 2024 : -0.7984
According to Novavax's latest financial reports the company has a price-to-book ratio of -0.7984.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Novavax - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -0.7953 | -42.29% |
| 2022-12-31 | -1.38 | -95.52% |
| 2021-12-31 | -30.8 | -371.78% |
| 2020-12-31 | 11.3 | -1735.05% |
| 2019-12-31 | -0.6922 | -83.57% |
| 2018-12-31 | -4.21 | -7.94% |
| 2017-12-31 | -4.58 | -92.57% |
| 2016-12-31 | -61.6 | -896.25% |
| 2015-12-31 | 7.74 | 25.48% |
| 2014-12-31 | 6.17 | 17.34% |
| 2013-12-31 | 5.26 | 50.85% |
| 2012-12-31 | 3.48 | 29.53% |
| 2011-12-31 | 2.69 | -41.12% |
| 2010-12-31 | 4.57 | 19.85% |
| 2009-12-31 | 3.81 | 32.66% |
| 2008-12-31 | 2.87 | -12.14% |
| 2007-12-31 | 3.27 | 21.37% |
| 2006-12-31 | 2.70 | -36.5% |
| 2005-12-31 | 4.24 | 9.54% |
| 2004-12-31 | 3.87 | -33.15% |
| 2003-12-31 | 5.80 | -27.94% |
| 2002-12-31 | 8.04 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 5.03 | -730.39% | 🇨🇭 Switzerland |
 Pfizer PFE | 1.61 | -301.75% | 🇺🇸 USA |
 AstraZeneca AZN | 6.21 | -878.39% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 5.16 | -745.84% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | 14.2 | -1,873.69% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 5.56 | -795.99% | 🇺🇸 USA |
 Agenus
AGEN | -1.65 | 106.68% | 🇺🇸 USA |
 NanoViricides NNVC | 1.04 | -230.34% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | -1.88 | 135.79% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.1549 | -119.40% | 🇺🇸 USA |